COMMUNIQUÉS West-GlobeNewswire

Milestone Scientific Reports Financial Results for Second Quarter 2026
14/08/2026
Medical Segment Revenue Grows 231% Year-Over-Year Enters Strategic Distribution Agreement to Expand CompuFlo® Access Across VA and Department of Defense Health Systems Reaffirms 2026 Outlook for Double-Digit Revenue [...]
Indiana Center for Recovery Named No. 1 Addiction Treatment Center in Indiana by Newsweek
14/08/2026
Indiana Center for Recovery in Bloomington ranks top in the state on Newsweek’s 2026 list for excellence in addiction treatment and mental health services. BLOOMINGTON, Ind., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Indiana [...]
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
14/08/2026
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD [...]
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
14/08/2026
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to [...]
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
14/08/2026
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients [...]
GT Biopharma Reports Second Quarter 2026 Financial Results
14/08/2026
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 [...]
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
14/08/2026
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed Rezatapopt NDA submission for platinum-resistant/ [...]
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
14/08/2026
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR [...]
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
14/08/2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
14/08/2026
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
14/08/2026
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss [...]
TOMI Environmental Solutions, Inc. Reports Second Quarter 2026 Financial Results
14/08/2026
Company Delivers 118% Q2 Revenue Growth, Reaffirms Full-Year 2026 Guidance of $12 Million (113% YoY Growth) FREDERICK, Md., Aug. 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global [...]
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
14/08/2026
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose [...]
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
14/08/2026
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the [...]
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
14/08/2026
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
14/08/2026
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – [...]
Sienna Announces August Dividend
14/08/2026
MARKHAM, Ontario, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
14/08/2026
Strategic project expands Zorronet’s presence in defense technology test and evaluation environments and includes site infrastructure, systems integration, a dedicated command-and-control center and coordination with [...]
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
14/08/2026
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current [...]

Pages